DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-hodgkin lymphoma

Molecular Cancer Therapeutics

Volumn 12, Issue 7, 2013, Pages 1255-1265

  Li, Dongwei ^a   Poon, Kirsten Achilles ^a   Yu, Shang Fan ^a   Dere, Randall ^a   Go, MaryAnn ^a   Lau, Jeffrey ^a   Zheng, Bing ^a   Elkins, Kristi ^a   Danilenko, Dimitry ^a   Kozak, Katherine R ^a   Chan, Pamela ^a   Chuh, Josefa ^a   Shi, Xiaoyan ^a   Nazzal, Denise ^a   Fuh, Franklin ^a   McBride, Jacqueline ^a   Ramakrishnan, Vanitha ^a   De Tute, Ruth ^b,c   Rawstron, Andy ^b,c   Jack, Andrew S ^c   Deng, Rong ^a   Chu, Yu Waye ^a   Dornan, David ^a   Williams, Marna ^a   Ho, William ^a   Ebens, Allen ^a   Prabhu, Saileta ^a   Polson, Andrew G ^a   more..

^a GENENTECH INC   (United States)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CNJ 1135; CYCLOPHOSPHAMIDE; DCDT 2980S; DOXORUBICIN; IMMUNOGLOBULIN G1 ANTIBODY; MCDT 2219A; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VEDOTIN; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HAPLORHINI; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 84880072016     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1173     Document Type: Article

References (19)

1. Bagg A. B cells behaving badly: a better basis to behold belligerence in B-cell lymphomas. Hematology 2011;2011:330-5.
2. Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology 2007:216-25.
3. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-5.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA: Cancer J Clin 2009;59:225-49.
5. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of nonhodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.
6. Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010;24:1566-73.
7. Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin's lymphoma. Blood 2007;110:616-23. (Pubitemid 47105400)
8. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocytespecific adhesion molecule that regulates antigen receptor signaling. Ann Rev Immunol 1997;15:481-504. (Pubitemid 27169290)
9. Barclay AN, Brown M, Law SKA, McKinght AJ, Tomlinson MG, Anton van der Merwe P. The leucocyte antigen facts book. San Diego, CA: Academic Press; 1997.
10. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704-13. (Pubitemid 46842705)
11. Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol 2011;71:175-82.
12. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004;103:1807-14. (Pubitemid 38268977)
13. Zein N, Poncin M, Nilakantan R, Ellestad GA. Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science 1989;244:697-9. (Pubitemid 19147681)
14. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84. (Pubitemid 36791396)
15. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009;114:2721-9.
16. Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 1999;44:395-402. (Pubitemid 29455585)
17. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34. (Pubitemid 39100467)
18. Ogura M, Uchida T, MacDonald DA, Hatake K, Davies A, Sangha R, et al. An open-label, phase I study of R-CVP in combination with inotuzumab ozogamicin in patients with relapsed/refractory CD22-positive B-cell non-hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2011;118:3715.
19. Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120:560-8.